Recruiting Osteogenesis Imperfecta Studies in Duarte
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
This is a multi-center, randomized, double-blinded, placebo controlled trial....
A Study of BGB-11417 in Participants With Myeloid Malignancies
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute m...
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Somet...
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need...
Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with...
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with ac...
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2...
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to v...
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is les...
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL)....
About Osteogenesis Imperfecta Clinical Trials in Duarte
Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.
There are currently 12 osteogenesis imperfecta clinical trials recruiting participants in Duarte, CALIFORNIA. These studies are seeking a combined 2,214 participants. Research is being sponsored by Priothera SAS, BeiGene, National Cancer Institute (NCI) and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Osteogenesis Imperfecta Clinical Trials in Duarte — FAQ
Are there osteogenesis imperfecta clinical trials in Duarte?
Yes, there are 12 osteogenesis imperfecta clinical trials currently recruiting in Duarte, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Duarte?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.
Are clinical trials in Duarte free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.
What osteogenesis imperfecta treatments are being tested?
The 12 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.
Data updated March 2, 2026 from ClinicalTrials.gov